Schrodinger Inc - Company Profile
Powered by 
All the sales intelligence you need on Schrodinger Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Schrodinger Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Schrodinger Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Schrodinger Inc (Schrodinger) is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin's lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. Schrodinger's other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company has operations in the US, Germany, Japan, the UK, India, Ireland, China and South Korea. Schrodinger is headquartered in New York, the US.
Headquarters
United States of America
Address
1540 Broadway, 24th Floor, New York, 10036
Website
www.schrodinger.com
Telephone
1 212 2955800
No of Employees
850
Industry
Technology and Communications
Ticker Symbol & Exchange
SDGR (NASD)
Revenue (2024)
$255.9M
23.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
44.8%
(2024 vs 2023)
Market Cap*
$1.3B
Net Profit Margin (2024)
XYZ
55.2%
(2024 vs 2023)
* As of and is in US$
Schrodinger Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline | Training Services | LiveDesign |
| SGR-1505 (MALT1) - Non-Hodgkin's Lymphoma | Support and Documentation | Schrodinger |
| SGR-2921 (CDC7) - Hematological Cancers and Solid Tumors | Solutions: | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In July, the company launched Bunsen, an agentic AI co-scientist. |
| 2026 | Contracts/Agreements | In January, the company partnered with Eli Lilly to integrate Lilly’s TuneLab platform into LiveDesign. |
| 2025 | Contracts/Agreements | In January, the company selected the Sapio Platform to make better data management, enhance lab efficiency, and accelerate the discovery of novel molecules. |
Competitor Comparison
| Key Parameters | Schrodinger Inc | Cadence Design Systems Inc | Simulations Plus Inc | Cresset BioMolecular Discovery Ltd | Biovia |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | New York | San Jose | Durham | Litlington | San Diego |
| State/Province | New York | California | North Carolina | Cambridgeshire | California |
| No. of Employees | 850 | 13,800 | 212 | 115 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Lynton | Chairman | Executive Board | 2018 | - |
| Ramy Farid, Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2002 | - |
| Richie Jain | Chief Financial Officer | Senior Management | 2025 | - |
| Jenny Herman | Senior Vice President; Chief Accounting Officer | Senior Management | 2021 | - |
| Karen Akinsanya, Ph.D. | Chief Strategy Officer; Head - Therapeutics Research and Development; President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer